The BioHub - by Avetix

In this episode of The BioHub Podcast , Max sits down with Andrew Obenshain, CEO of Inventiva. Andrew brings more than 20 years of experience across global drug development, regulatory strategy, and commercialization. Before joining Inventiva, he led bluebird bio through its transformation into a global commercial-stage gene therapy company and previously held senior leadership roles at Shire and...

Today, I'm delighted to welcome Eduardo, CEO of Citryll Therapeutics. Eduardo has built his career at the intersection of science, innovation, and business, leading the development of transformative therapies designed to address serious autoimmune and inflammatory diseases. With extensive experience in the biotechnology industry, Eduardo has played a key role in guiding companies from scientif...

In this episode of The BioHub Podcast by Avetix, Ben is joined by Michael Rome, Managing Director at Foresite Capital. Michael brings a unique perspective across biotech investing, company formation, therapeutics strategy, and public markets. The conversation explores how great biotech companies are built, what separates strong science from a fundable opportunity, and how investors think about tim...

Today, I'm delighted to welcome Luke Henry, Chief Business Officer and Chief Operating Officer at Quell Therapeutics, a company at the forefront of engineering the next generation of regulatory T cell, or Treg, therapies for immune-mediated diseases. Quell is pioneering a new approach to treating autoimmune and inflammatory diseases, as well as improving outcomes in organ transplantation. Rath...

Rick Batycky, CEO of Nocion Therapeutics, joins The BioHub Podcast by Avetix to discuss the company’s work in chronic cough and neurogenic inflammation. Rick talks about the scale of the unmet need in chronic cough, why the condition remains so difficult to treat, and how Nocion is approaching the biology differently. He also shares insight into the company’s lead programme, its upcoming pivotal-s...

Welcome back to another episode of the BioHub Podcast. Today, we're delighted to be joined by Patrick Mooney, CEO of SpyGlass Pharma. Patrick has built an impressive career in ophthalmology, beginning in sales and progressing through a variety of leadership roles to become one of the industry's most respected executives. At SpyGlass Pharma, the mission is simple: put patients first. The co...

In this episode of The BioHub Podcast, Max sits down with Dr. Sandeep Kulkarni, Co-Founder and CEO of Zura Bio. Sandeep's career has spanned consulting, investing, and operating roles across biotech, including positions at BCG, Roivant, and Immunovant, before going on to co-found Tourmaline Bio and now lead Zura Bio. Zura is a clinical-stage biotechnology company focused on developing novel th...

In this episode of The BioHub, Amber is joined by Trevor Martin, Co-Founder and CEO of Mammoth Biosciences. Mammoth Biosciences is developing next-generation CRISPR technologies with the goal of unlocking the full potential of programmable medicine. Founded alongside Nobel Prize winner Jennifer Doudna, the company has built a platform focused on discovering and engineering novel CRISPR systems for...

In this episode of The BioHub Podcast, Max sits down with Sean MacDonald, CEO of Kainova Therapeutics. Sean has spent more than two decades in biotech, helping build companies through strategy, fundraising, business development, and corporate leadership. Today, he leads Kainova Therapeutics, a clinical-stage company focused on unlocking the potential of GPCR biology in immuno-oncology and inflamma...

In this episode of The BioHub Podcast, Max sits down with Cameron Pitt, Co-Founder and COO of Quanta Therapeutics. Cameron's career has taken him from academic research at Stanford and UCSF, to venture investing at Versant Ventures and Sofinnova Investments, before helping form and build Quanta Therapeutics from the ground up. Quanta is focused on one of the biggest challenges in oncology: tar...

In this episode of The BioHub Podcast , Max sits down with Geert Kersten, Chairman and CEO of CEL-SCI Corporation. Geert has led CEL-SCI for nearly three decades, overseeing the development of the company's lead immunotherapy candidate, Multikine, and navigating one of the longest and most challenging journeys in biotech. In this conversation, we discuss the realities of building a biotech company...

In this episode of The BioHub Podcast , Max sits down with Leonard Mazur, Chairman and CEO of Citius Pharmaceuticals. Leonard is a seasoned entrepreneur and pharmaceutical executive who has spent decades building, scaling, and commercializing healthcare companies. Throughout his career, he has founded multiple successful businesses, led major transactions, and helped bring innovative therapies to...

In this episode of The BioHub Podcast , Max sits down with Derek Small, Founder and Managing Director of Luson Bioventures. Over the past two decades, Derek has built a reputation as one of biotech's leading venture creators, founding and leading multiple companies across neuroscience and CNS drug development. Through Luson, he has helped launch, finance, and scale businesses from inception, raisi...

Today's guest is Edward Ahn, CEO of MEDIPOST Inc., a biotechnology company at the forefront of regenerative medicine and stem cell therapeutics. Based in Cambridge, Massachusetts, MEDIPOST is leading the global development of innovative cell therapies designed to address inflammation-driven degenerative diseases, with a mission to move beyond symptom management and toward true disease modifica...

In this episode of The BioHub Podcast , Max sits down with Randy Teel, President and CEO of Arvinas. Randy joined Arvinas in 2018 as Vice President of Corporate Development and has since helped guide the company through a period of significant growth, ultimately stepping into the CEO role. Today, Arvinas is one of the pioneers in targeted protein degradation, using its PROTAC platform to develop t...

Matt Erick, Chief Commercial Officer for Advanced Markets at Biocon Biologics, joins Max on The BioHub Podcast. With more than two decades of experience across pharma, biologics, distribution, and healthcare services, Matt has helped shape commercial strategy across some of the industry's most complex and competitive markets. In this conversation, we discuss Biocon's expansion into the U.S...

We were delighted to be joined by Dr. David Solomon, Chief Executive Officer of Thalia Therapeutics, onto The BioHub! David brings more than three decades of leadership experience across the biotechnology, pharmaceutical, and healthcare sectors, having led multiple publicly listed and private biotech companies throughout Europe and the United States. Throughout his career, he has played a key role...

Today on the podcast, we’re joined by Peter Smith, co-founder and CEO of — a company pioneering a new frontier in RNA-processing therapeutics. Peter has spent more than two decades at the forefront of oncology and drug discovery, with leadership roles spanning Takeda, Millennium Pharmaceuticals, and H3 Biomedicine before launching Remix to tackle diseases through precision RNA modulation. Remix is...

In this episode of The BioHub Podcast , Max sits down with Ben Zimmer, CEO of Priovant Therapeutics. Ben was among the first ten employees at Roivant, helping incubate and launch multiple biotech companies before going on to found Priovant in 2021. Priovant is a clinical-stage biotech focused on developing therapies for severe autoimmune diseases — one of the most active and fast-moving areas in b...

Tosh joins the podcast to talk through Navigator Medicines' bispecific approach to Hidradenitis Suppurativa. Giving us the full picture, from NAV-240's Korean-origins & the 2024 $100million Series A lead by RA Capital & Forbion, to the work that went into their half-life extended next-gen molecule NAV-242 & the speedy clinical development plan that could lead to a step change in HS pat...

In this episode, Ben sits down with Kevin Finney, President and CEO of Autobahn Therapeutics, for a conversation on biotech leadership, CNS drug development, and what it takes to build companies around difficult but high-impact areas of medicine. Kevin brings deep experience across company formation, financing, business development, and exits, including leadership roles at Abide Therapeutics, whic...

Today we’re joined by Shane Hegarty, a neuroscientist turned biotech operator who’s spent his career at the intersection of cutting-edge brain science and therapeutic innovation. From award-winning Parkinson’s research to helping shape the mission at Axonis Therapeutics, Shane has a front-row seat to one of the most exciting areas in medicine: repairing the nervous system. We talk about the scienc...

In this episode, Ben sits down with Asa Abeliovich, MD, PhD, Founder and CEO of Leal Therapeutics, to talk about Leal’s mission to develop precision medicines for some of the most complex and underserved neurodegenerative diseases. The conversation explores how Leal is using human genetics, disease biology, and translational neuroscience to build a pipeline focused on conditions such as Parkinson’...

Today’s guest is Joe Jimenez, one of the most influential leaders in modern biopharma. Joe previously served as CEO of Novartis, where he led the company through a major strategic transformation and helped establish it as one of the world’s leading innovative medicines companies. Today, he is the co-founder and managing director of Aditum Bio, a biotech venture firm focused on building breakthroug...

In this episode of The BioHub Podcast, Max sits down with Bruce Leuchter, co-founder and CEO of Neurvati Neurosciences. Bruce’s career spans clinical neuroscience, psychiatry, investment banking, and biotech company building — giving him a uniquely broad perspective on the future of CNS drug development. Neurvati, a Blackstone Life Sciences portfolio company, is focused on identifying and advancin...